Research progress of the chemoprevention agents for breast cancer
10.3760/cma.j.issn.1673-4203.2020.01.013
- VernacularTitle: 乳腺癌化学预防相关药物的研究进展
- Author:
Song WU
1
;
Jiaxin ZHANG
2
Author Information
1. Dalian Medical University, Dalian 116044, China
2. Department of Thyroid and Breast Surgery, College of Clinical Medicine, Yangzhou University, Yangzhou 225001, China
- Publication Type:Review
- Keywords:
Breast neoplasms;
Chemoprevention;
Aspirin;
Flavones;
Poly(ADP-ribose) polymerases
- From:
International Journal of Surgery
2020;47(1):61-65
- CountryChina
- Language:Chinese
-
Abstract:
As one of the most common malignant tumors in women, breast cancer has the characteristics of high incidence, strong invasion, easy recurrence and metastasis. Although the mortality of breast cancer has decreased in recent years, its incidence has not been effectively controlled. Chemoprevention is a kind of preventive measure to reduce the incidence of disease by using natural or synthetic chemical drugs to prevent the asymptomatic high-risk population. At present, only estrogen receptor modulators and aromatase inhibitors are allowed to be used in clinical chemoprevention of breast cancer. Therefore, researcher should actively take measures to find new high-efficient, low-toxic chemoprevention agents that take into account the majority of the population. The main purpose of this review is to summarize the mechanisms and related experimental studies of six chemoprevention agents for breast cancer including estrogen receptor modulators, include aromatase inhibitors, aspirin, metformin, flavones and poly(ADP-ribose) polymerases inhibitors.
